Nephros, Inc. is a commercial-stage company that develops and markets point-of-use water filtration solutions, with a core focus on medical-grade applications. The company operates two primary business segments: medical water filtration and commercial water filtration. Its medical portfolio includes infection control filters, featuring microfilters and ultrafilters that retain bacteria, viruses, and endotoxins, and dialysis water filters designed for hemodialysis treatment. These medical-grade products are FDA 510(k)-cleared as Class II medical devices. The commercial segment offers carbon-based and carbon-free filters that improve taste, reduce scale and biofilm, and remove contaminants such as lead, cysts, and Total PFAS. Nephros serves hospitals, dialysis centers, laboratories, manufacturing facilities, aviation environments, and foodservice and hospitality venues. The company sells through a combination of direct sales and value-added resellers (VARs), including a partner focused on the food service and hospitality sectors. Founded in 1997 with a focus on the end-stage renal disease marketplace, Nephros acquired Biocon 1, LLC and Aether Water Systems, LLC in 2019 to expand its commercial filtration lineup.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Specialty Chemicals Homepage nephros.com
Sector Basic Materials IR page nephros.com/investors
Tags
water filtration, medical devices, infection control, dialysis, hollow fiber membranes, pfas removal, point-of-use filtration, healthcare facilities, foodservice, industrial filtration, Biocon 1 LLC, Aether Water Systems LLC
Press page —

Metrics

Valuation  
Market cap $ 30.871M
Market cap (USD) $ 30.871M
P/E 25.82
PEG —
P/BV 2.46
P/S 1.43
P/OCF -33.92
P/FCF 18.77
Dividend yield —
Turnover / mcap —
Returns  
ROE 12.7%
ROI 24.8%
ROIC 23.6%
Profit margin 6.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 3
Quality score 17.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007
Revenue 18.789M 14.162M 14.238M 9.975M 10.404M 8.561M 10.334M 5.687M 3.809M 2.32M 1.944M 1.748M 1.74M 1.807M 2.214M 2.938M 2.661M 1.473M 1.196M
Net profit 1.194M 74K -1.575M -7.106M -3.867M -4.526M -3.42M -3.402M -809K -3.032M -3.088M -7.371M -3.698M -3.262M -2.36M -1.933M -2.026M -6.337M -26.356M
Free cash flow 1.645M -547K 752K -3.371M -1.453M -7.142M -2.29M — — -2.157M -3.828M — -3.583M -1.555M — -1.322M -2.64M -5.822M -6.587M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007
Share price 4.88 1.47 3.46 1.15 5.9 8.58 9.95 0.45 0.5 0.37 0.21 0.76 0.39 — — — 1.95 — —
Price performance 12m 2.32 -0.58 2 -0.8 -0.31 -0.14 21.12 -0.1 0.37 0.71 -0.72 0.97 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 388,000 836,000 1.45M 1.05M 1.36M 1.64M 1.29M 1.5M 1.78M 2.41M
↳ YoY growth -2.3% +115.5% +73.7% -28.0% +30.5% +20.3% -21.6% +16.3% +19.1% +35.5%
↳ 5y CAGR +64.1% +56.9% +28.0% +33.4% +9.0% +0.6% +11.3% +12.1%
Lease liabilities (USD) — — 621,000 1.15M 1.13M 949,000 1.02M 1.84M 1.41M 1.06M
Cash and deposits (USD) — — — 4.17M 8.25M 6.97M 3.63M 4.31M 3.76M 5.4M
Intangible assets (USD) 2.25M 2.25M 590,000 548,000 506,000 1.54M 423,000 381,000 349,000 318,000
Right-of-use assets (USD) — — 613,000 1.11M 1.04M 867,000 972,000 1.8M 1.36M 1M
Cash flow detail
Operating cash flow (USD) -2.11M -77,000 -3.66M -2.28M -6.9M -1.42M -3.23M 827,000 -492,000 1.65M
Purchases of property, plant and equipment (USD) -45,000 — — -14,000 -239,000 -36,000 -137,000 -75,000 -55,000 —
Change in receivables (cash effect) (USD) -17,000 -416,000 -484,000 392,000 -333,000 -278,000 357,000 -221,000 -285,000 -633,000
Change in inventories (cash effect) (USD) 103,000 -195,000 -1.08M -735,000 -2.76M 296,000 915,000 387,000 -407,000 -685,000
Change in payables (cash effect) (USD) -76,000 268,000 -130,000 119,000 -538,000 908,000 -593,000 133,000 -220,000 259,000
Interest paid (cash effect) (USD) -113,000 -148,000 -150,000 -139,000 -93,000 -41,000 -19,000 -2,000 -2,000 -1,000
Income taxes paid (cash effect) (USD) -11,000 -7,000 -4,000 -5,000 -22,000 -79,000 — — — —
Share-based compensation (USD) 551,000 772,000 985,000 1.33M 779,000 1.26M 982,000 1.05M 153,000 296,000
Operating cash flow before change in receivables (USD) -2.1M 339,000 -3.18M -2.67M -6.57M -1.14M -3.59M 1.05M -207,000 2.28M
Free cash flow (OCF - PPE - intangibles) (USD) -2.16M — — -2.29M -7.14M -1.45M -3.37M 752,000 -547,000 —
Income detail
Research and development expense (USD) 1.08M 1M 1.54M 3.09M 2.76M 2.17M 1.26M 873,000 906,000 1.34M
↳ 5y CAGR +19.1% +9.7% +13.3% +31.7% +27.3% +15.0% +4.6% -10.7% -21.8% -13.5%
Total comprehensive income (USD) -3.04M -799,000 -3.41M -3.43M -4.52M -3.88M -7.12M -1.58M — —
Comprehensive income to owners (USD) -3.04M -799,000 -3.41M -3.19M -4.76M -4.12M -7.4M -1.58M — —
Provision for credit losses (USD) 35,000 — 40,000 15,000 11,000 1,000 -1,000 11,000 — —
Credit cost ratio (credit losses / average receivables) (%) 8.9% — 3.5% 1.2% 0.9% 0.1% 0.1% 0.8% — —
Reported Mar 20, 2017 Feb 26, 2018 May 8, 2019 May 6, 2020 Mar 1, 2021 Aug 15, 2022 Mar 23, 2023 Mar 15, 2024 Mar 24, 2025 Mar 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On November 10, 2026, Lisa Nettis notified the Board of Directors (the “Board”) of Nephros, Inc. (the “Company”) of her resignation from the Board, effective on November 26, 2026. Ms. Nettis’ decision to resign was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

South Orange NJ 07079 Bull 0 Bear 0 Routine

Call: 201 343 5202

nephros.com

Nephros Announces Date for 2026 Annual Meeting of Stockholders

2026 Annual Meeting of Stockholders to Be Held Virtually on November 25, 2026

SOUTH ORANGE, NJ – October 13, 2026 – Nephros, Inc. (NASDAQ: [NEPH]) (“Nephros” or the “Company”) today announced that its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) will be held on Wednesday, November 25, 2026, at 11:00 a.m., Eastern Time. The meeting will be held virtually and conducted live via webcast. The time, agenda and instructions for attending the 2026 Annual Meeting will be set forth in the Company’s definitive proxy statement. That proxy statement will be sent to stockholders entitled to notice of and to vote at the 2026 Annual Meeting.

The Board of Directors has fixed the close of business on September 30, 2026 as the record date for determining the stockholders entitled to notice of, and to vote at, the 2026 Annual Meeting.

The 2026 Annual Meeting will be held more than 30 days after the anniversary of the Company’s 2025 Annual Meeting of Stockholders, which was held on June 16, 2025.

South Orange NJ 07079 Bull 3 Bear 0 Results

Call: 201 343 5202

nephros.com

Nephros Announces Strong Third Quarter 2026 Financial Results

Year Over Year Net Revenue Growth of 18% and Core Programmatic Revenue Growth of 8% for the Three Months Ended September 30, 2026.

SOUTH ORANGE, NJ, November 5, 2026 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2026.

Financial Highlights

● Net revenue increased 18% to $5.6 million, compared to $4.8 million in the third quarter of 2025

● Net income was $0.5 million, compared to net income of $0.3 million in the third quarter of 2025

● Adjusted EBITDA was $0.6 million, compared to $0.4 million in the third quarter of 2025

“The third quarter of 2026 continued the strong momentum we have built across Nephros,” said Robert Banks, President and Chief Executive Officer of Nephros. “Net revenue increased approximately 18% over the prior-year quarter to $5.6 million, following the record $6.0 million we reported in the second quarter.

Prompts

Nephros, Inc. (ticker NEPH), listed in United States.

ETFs Holding Nephros, Inc.

ETF Weight in ETF Shares Market value As of
DXUV 0.00% 1,419 $ 4,696.89 Nov 12, 2026
DFSU 0.00% 409 $ 1,353.79 Nov 12, 2026
DCOR 0.00% 4,795 $ 15.871K Nov 12, 2026
DFAC 0.00% 7,536 $ 24.944K Nov 12, 2026